Track topics on Twitter Track topics that are important to you
The best-case scenario for Gilead wasn't an FDA approval of Kymriah, but a rejection based on some reason other than the fact that it was a CAR-T therapy. While it's hard to argue that Kymriah getting approved is good news for Gilead, it seems likely that some investors took the approval as a sign that Gilead is making the right decision buying Kite in the first place.
Original Article: Are You Buying Gilead Sciences, Inc. for the Wrong Reason?NEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...